![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
PY Law and HH Loh
Department of Pharmacology, University of Minnesota, Minneapolis 55455.
In neuroblastoma x glioma NG108-15 hybrid cells, opioid agonists inhibited both basal and prostaglandin E1-stimulated adenylate cyclase activities assayed in the presence of the phosphodiesterase (PDE) inhibitors isobutylmethylxanthine and ZK62711 (rolipram). However, when intracellular [3H]cAMP was measured in the absence of the PDE inhibitors the maximal inhibitory level was increased, using the opioid agonist D-Ala2,D-Leu5-enkephalin. This increase in opioid activity was due to agonist stimulation of cAMP degradation, because when the degradation rate of [3H] cAMP was measured in intact hybrid cells it was observed to increase from the control value of 0.495 +/- 0.003 min- 1 to 0.760 +/- 0.003 min-1 in the presence of 1 microM D-Ala2,D-Leu5- enkephalin; this was reversed by naloxone. Dose-dependent studies with various opioid agonists, partial agonists, and antagonists revealed that there was a direct correlation between the abilities of these opioid ligands to inhibit adenylate cyclase activity and to stimulate PDE activity, with enkephalin and its analogs being the most potent agonists. Chronic agonist treatment also resulted in a reduction of the opioid agonist stimulation of cAMP degradation, with an apparent decrease in the PDE activity upon addition of naloxone after chronic treatment. However, treatment of the hybrid cells with pertussis toxin, which attenuated the agonist inhibition of adenylate cyclase activity, did not abolish this opioid response. When selective inhibitors for various types of PDE were used, the type I PDE inhibitor W-7 attenuated the opioid effect, whereas the type II PDE inhibitor trequinsin (HL725), the type III PDE inhibitor indolidan, and the type IV PDE inhibitor rolipram had no effect on opioid-stimulated cAMP degradation. The stimulation of type I PDE activity by delta-opioid receptors was independent of extracellular Ca2+ and was not observed with membrane preparations. Therefore, in NG108-15 cells delta-opioid receptors regulate intracellular cAMP levels by coupling to a pertussis toxin- insensitive guanine nucleotide-binding protein, resulting in an increase in intracellular Ca2+ and in Ca2+/calmodulin-dependent PDE activity.
This article has been cited by other articles:
|
|
 |
|
  E. V. Varga, M. K. Rubenzik, D. Stropova, M. Sugiyama, V. Grife, V. J. Hruby, K. C. Rice, W. R. Roeske, and H. I. Yamamura Converging Protein Kinase Pathways Mediate Adenylyl Cyclase Superactivation upon Chronic {delta}-Opioid Agonist Treatment J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 109 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-S. Bian, W.-M. Zhang, J.-M. Pei, and T.-M. Wong The Role of Phosphodiesterase in Mediating the Effect of Protein Kinase C on Cyclic AMP Accumulation upon kappa -Opioid Receptor Stimulation in the Rat Heart J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 1065 - 1070. [Abstract] [Full Text]
|
|
|
|
|
|
E. V. Varga, D. Stropova, T. Kim, M. Wang, W. R. Roeske, and H. I. Yamamura Coupling of Human delta -Opioid Receptor to Retinal Rod Transducin in Chinese Hamster Ovary Cells J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 209 - 214. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. M. Quock, T. H. Burkey, E. Varga, Y. Hosohata, K. Hosohata, S. M. Cowell, C. A. Slate, F. J. Ehlert, W. R. Roeske, and H. I. Yamamura The delta -Opioid Receptor: Molecular Pharmacology, Signal Transduction, and the Determination of Drug Efficacy Pharmacol. Rev., September 1, 1999; 51(3): 503 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Wang, W. Sadee, and J. M. Quillan Calmodulin Binding to G Protein-coupling Domain of Opioid Receptors J. Biol. Chem., July 30, 1999; 274(31): 22081 - 22088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Pepe, R.-P. Xiao, C. Hohl, R. Altschuld, and E. G. Lakatta `Cross Talk' Between Opioid Peptide and Adrenergic Receptor Signaling in Isolated Rat Heart Circulation, April 15, 1997; 95(8): 2122 - 2129. [Abstract] [Full Text]
|
|
|
|
|
|
T. Avidor-Reiss, M. Bayewitch, R. Levy, N. Matus-Leibovitch, I. Nevo, and Z. Vogel Adenylylcyclase Supersensitization in µ-Opioid Receptor-transfected Chinese Hamster Ovary Cells Following Chronic Opioid Treatment J. Biol. Chem., December 15, 1995; 270(50): 29732 - 29738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Belcheva, M. Szucs, D. Wang, W. Sadee, and C. J. Coscia {micro}-Opioid Receptor-mediated ERK Activation Involves Calmodulin-dependent Epidermal Growth Factor Receptor Transactivation J. Biol. Chem., August 31, 2001; 276(36): 33847 - 33853. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
